- Home
- TLNC vs OVID Comparison
TLNC vs OVID Comparison
Compare TLNC & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.19
Company Overview
Basic Information| Metric | TLNC | OVID |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.9M | 365.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TLNC | OVID |
|---|---|---|
| Price | $10.20 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 62.3K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $9.94 | $0.24 |
| 52 Week High | $10.26 | $2.72 |
Technical Indicators
Market Signals| Indicator | TLNC | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 54.73 |
| Support Level | $10.10 | $1.31 |
| Resistance Level | $10.26 | $2.38 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 68.75 | 37.72 |
Price Performance
Historical Comparison TLNC
OVID
About TLNC Talon Capital Corp. Class A Ordinary Shares
Talon Capital Corp is a newly organized blank check company.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.